LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Merus NV

Cerrado

SectorSalud

41.4 3.45

Resumen

Variación precio

24h

Actual

Mínimo

39.13

Máximo

41.75

Métricas clave

By Trading Economics

Ingresos

-66M

-96M

Ventas

17M

26M

BPA

-1.4

Margen de beneficio

-364.218

Empleados

260

EBITDA

-88M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+122.68% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

302M

2.9B

Apertura anterior

37.95

Cierre anterior

41.4

Noticias sobre sentimiento de mercado

By Acuity

48%

52%

170 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Merus NV Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 may 2025, 22:52 UTC

Ganancias
Principales Movimientos del Mercado

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 may 2025, 20:37 UTC

Principales Noticias
Ganancias

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 may 2025, 00:00 UTC

Charlas de Mercado

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 may 2025, 23:47 UTC

Charlas de Mercado

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 may 2025, 23:38 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 may 2025, 23:38 UTC

Charlas de Mercado

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 may 2025, 23:14 UTC

Principales Noticias

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 may 2025, 22:46 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 may 2025, 21:58 UTC

Ganancias

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 may 2025, 21:24 UTC

Ganancias

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 may 2025, 20:56 UTC

Charlas de Mercado

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 may 2025, 20:54 UTC

Charlas de Mercado
Ganancias

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 may 2025, 20:54 UTC

Ganancias

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 may 2025, 20:51 UTC

Ganancias

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 may 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

15 may 2025, 20:50 UTC

Adquisiciones, fusiones, absorciones

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 may 2025, 20:50 UTC

Ganancias

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 may 2025, 20:26 UTC

Principales Noticias

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 may 2025, 20:25 UTC

Ganancias

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Comparación entre iguales

Cambio de precio

Merus NV Esperado

Precio Objetivo

By TipRanks

122.68% repunte

Estimación a 12 meses

Media 89.25 USD  122.68%

Máximo 110 USD

Mínimo 67 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Merus NV Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

15

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

39.445 / 44.36Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

170 / 382 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.